(Q33945668)

30 July 2017

title

Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials (English)

1 reference

30 July 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

1

Nadine Houede

1 reference

30 July 2017

Peter F Thall

2

1 reference

30 July 2017

Hoang Nguyen

series ordinal

3

1 reference

30 July 2017

Xavier Paoletti

series ordinal

4

1 reference

30 July 2017

Andrew Kramar

series ordinal

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

10 August 2009

1 reference

30 July 2017

1 reference

30 July 2017

volume

66

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

532-540

1 reference

maintained by WikiProject

30 July 2017

WikiProject Mathematics

0 references

cites work

Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

Cancer phase I clinical trials: efficient dose escalation with overdose control.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

Design and analysis of phase I clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes

5 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1541-0420.2009.01302.X

An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1541-0420.2009.01302.X

Dose-finding based on efficacy-toxicity trade-offs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1541-0420.2009.01302.X

Dose‐Finding with Two Agents in Phase I Oncology Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1541-0420.2009.01302.X

The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1541-0420.2009.01302.X

Recent developments in adaptive designs for Phase I/II dose-finding studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1541-0420.2009.01302.X

A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893272

Patient-specific dose finding based on bivariate outcomes and covariates

29 October 2018

1 reference

12 December 2020

Dose-finding designs for HIV studies

1 reference

12 December 2020

A new dose-finding design for bivariate outcomes

1 reference

12 December 2020

A method for the detailed assessment of the appropriateness of medical technologies

1 reference

12 December 2020

Bivariate isotonic design for dose-finding with ordered groups

1 reference

12 December 2020

Simultaneously optimizing dose and schedule of a new cytotoxic agent

1 reference

12 December 2020

Sequential designs for phase I clinical trials with late-onset toxicities

1 reference

12 December 2020

10.1111/J.1541-0420.2009.01302.X

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference